163 related articles for article (PubMed ID: 3967084)
1. Multiple myeloma: significance of plasmablastic subtype in morphological classification.
Greipp PR; Raymond NM; Kyle RA; O'Fallon WM
Blood; 1985 Feb; 65(2):305-10. PubMed ID: 3967084
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of plasma cell morphology in multiple myeloma.
Carter A; Hocherman I; Linn S; Cohen Y; Tatarsky I
Cancer; 1987 Sep; 60(5):1060-5. PubMed ID: 3607725
[TBL] [Abstract][Full Text] [Related]
3. Prognostic relevance of morphological classification in multiple myeloma.
Murakami H; Nemoto K; Sawamura M; Tamura J; Matsushima T; Naruse T; Tsuchiya J; Sato S; Shiamano S; Shinonome S
Acta Haematol; 1992; 87(3):113-7. PubMed ID: 1642091
[TBL] [Abstract][Full Text] [Related]
4. [Utility of the examination of plasma-cell morphology in the study of multiple myeloma].
Moro MJ; Portero JA; Gascón A; Hernández JM; Ortega F; Jiménez R; Guerras L; Martínez M; Casanova F; Sanz MA
Sangre (Barc); 1992 Jun; 37(3):175-9. PubMed ID: 1440094
[TBL] [Abstract][Full Text] [Related]
5. Plasma cell morphology in multiple myeloma and related disorders.
Ribourtout B; Zandecki M
Morphologie; 2015 Jun; 99(325):38-62. PubMed ID: 25899140
[TBL] [Abstract][Full Text] [Related]
6. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma.
Rajkumar SV; Fonseca R; Lacy MQ; Witzig TE; Therneau TM; Kyle RA; Litzow MR; Gertz MA; Greipp PR
J Clin Oncol; 1999 May; 17(5):1551-7. PubMed ID: 10334543
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of plasma cell morphology in multiple myeloma.
Paule B; Quillard J; Bisson M; Kahn MF; Massias P
Nouv Rev Fr Hematol (1978); 1988; 30(4):209-12. PubMed ID: 3194186
[TBL] [Abstract][Full Text] [Related]
8. [Usefulness of the modified Greipp's morphological classification of multiple myeloma cells].
Ohata M; Nakamura S; Kuroyama Y
Rinsho Byori; 1996 Dec; 44(12):1189-95. PubMed ID: 8990939
[TBL] [Abstract][Full Text] [Related]
9. Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphology.
Goasguen JE; Zandecki M; Mathiot C; Scheiff JM; Bizet M; Ly-Sunnaram B; Grosbois B; Monconduit M; Michaux JL; Facon T
Leuk Res; 1999 Dec; 23(12):1133-40. PubMed ID: 10613359
[TBL] [Abstract][Full Text] [Related]
10. Genetic Basis of Extramedullary Plasmablastic Transformation of Multiple Myeloma.
Liu Y; Jelloul F; Zhang Y; Bhavsar T; Ho C; Rao M; Lewis NE; Cimera R; Baik J; Sigler A; Sen F; Yabe M; Roshal M; Landgren O; Dogan A; Xiao W
Am J Surg Pathol; 2020 Jun; 44(6):838-848. PubMed ID: 32118627
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous localization of plasmablastic multiple myeloma with heterotopic expression of CD3 and CD4: Skin involvement revealing systemic disease.
Varricchio S; Pagliuca F; Travaglino A; Gallo L; Villa MR; Mascolo M
J Cutan Pathol; 2019 Aug; 46(8):619-622. PubMed ID: 31025408
[TBL] [Abstract][Full Text] [Related]
12. Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group.
Greipp PR; Leong T; Bennett JM; Gaillard JP; Klein B; Stewart JA; Oken MM; Kay NE; Van Ness B; Kyle RA
Blood; 1998 Apr; 91(7):2501-7. PubMed ID: 9516151
[TBL] [Abstract][Full Text] [Related]
13. Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report.
Sher T; Miller KC; Lee K; Chanan-Khan A
Clin Lymphoma Myeloma; 2009 Aug; 9(4):328-30. PubMed ID: 19717386
[TBL] [Abstract][Full Text] [Related]
14. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma.
Greipp PR; Katzmann JA; O'Fallon WM; Kyle RA
Blood; 1988 Jul; 72(1):219-23. PubMed ID: 3291982
[TBL] [Abstract][Full Text] [Related]
15. Plasma cell maturity as a predictor of prognosis in multiple myeloma.
Iriyama N; Miura K; Hatta Y; Uchino Y; Kurita D; Takahashi H; Sakagami H; Sakagami M; Kobayashi Y; Nakagawa M; Ohtake S; Iizuka Y; Takei M
Med Oncol; 2016 Aug; 33(8):87. PubMed ID: 27383407
[TBL] [Abstract][Full Text] [Related]
16. Morphologic heterogeneity and plasmablastic transformation in advanced plasmacytic/plasmablastic myeloma: a study of 35 serial bone marrow biopsies in 9 patients.
Paule B; Quillard J; Bennet P; Mariette X; Bisson M
Nouv Rev Fr Hematol (1978); 1989; 31(3):203-8. PubMed ID: 2616267
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow infiltration by plasmablastic neoplasm: plasmablastic myeloma or plasmablastic lymphoma?
Eladl E; Chang H
Blood; 2021 Mar; 137(9):1268. PubMed ID: 33661296
[No Abstract] [Full Text] [Related]
18. Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging.
Bartl R; Frisch B; Burkhardt R; Fateh-Moghadam A; Mahl G; Gierster P; Sund M; Kettner G
Br J Haematol; 1982 Jul; 51(3):361-75. PubMed ID: 7104223
[TBL] [Abstract][Full Text] [Related]
19. Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma.
Greipp PR; Kyle RA
Blood; 1983 Jul; 62(1):166-71. PubMed ID: 6407546
[TBL] [Abstract][Full Text] [Related]
20. Critical study of staging in multiple myeloma.
Pennec Y; Mottier D; Youinou P; Asselain B; Chavance M; Le Goff P; Le Prise PY; Miossec P; Le Menn G
Scand J Haematol; 1983 Feb; 30(2):183-90. PubMed ID: 6860419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
